cCeLL - In vivo
VPIX MEDICAL, INC. · Decision date Oct 16, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-16 for cCeLL - In vivo, a traditional 510(k) submitted by VPIX Medical, Inc. of Daejeon, KR, under 510(k) number K260315. The device falls under regulation 882.1480 with classification product code GWG and subsequent product code OWN, in the Neurology specialty and review panel. The application was received 01/30/2026 and was not reviewed by a third party.
SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The record does not describe the device's components, the specific change or comparison to a predicate, or any clinical data, and no summary statement is present in the public information. The page lists no combination product and no authorized predetermined change control plan. Details of the cleared indications and any performance testing remain unknown from this record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260315
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- VPIX MEDICAL, INC.
- Product code
- GWG
- Decision code
- SESE
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Endoscope, Neurological.
- Applicant
- VPIX MEDICAL, INC.
- Product code
- GWG
- FDA device class
- 2
FDA decision timeline
K260315 received
Application receipt date recorded by FDA.
K260315 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code GWG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Karl Storz SE & CO. KG | 510(k) clearance | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
VPIX MEDICAL, INC.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Daejeon
Sources and methodology
- Original FDA record: K260315
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records